
Compass Pathways’ COMP360 psilocybin formulation reveals promising Phase 3 results for treatment-resistant depression, maintaining remission over six months.

A recent study in JAMA uncovers genetic variants explaining why 10% of patients don’t respond well to GLP-1…

A groundbreaking study reveals a new pathway involving hydrogen sulfide that could transform our understanding of Alzheimer’s disease…

Recent research reveals a groundbreaking connection between CSE enzyme activity and Alzheimer’s, spotlighting hydrogen sulfide’s protective role in…

The 2026 Breakthrough Prize celebrates leaders in gene therapy and sickle cell research, awarding $3 million each to…

A groundbreaking study from the University of Geneva has developed an AI-driven stool test that detects colorectal cancer…

Researchers identify ‘zombie’ immune cells that accelerate aging and fatty liver disease through persistent inflammation, unveiling new treatment…

Pfizer’s insulin efsitora alfa matches daily Lantus in efficacy over 52 weeks, potentially transforming diabetes care with its…

The World Health Organization’s recent addition of three diseases to its Neglected Tropical Diseases list marks a significant…

Learn how to use the S.M.A.R.T. framework to turn your fitness tracker data into actionable, achievable goals for…